---
layout: post
title: "Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal"
date: 2026-02-05 19:01:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-27014
original_published: 2022-12-13 00:00:00 +0000
significance: 8.00
---

# Advisory Committee; Cardiovascular and Renal Drugs Advisory Committee; Renewal

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 13, 2022 00:00 UTC
**Document Number:** 2022-27014

## Summary

The Food and Drug Administration (FDA) is announcing the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Cardiovascular and Renal Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the August 27, 2024, expiration date.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/13/2022-27014/advisory-committee-cardiovascular-and-renal-drugs-advisory-committee-renewal)
- API: https://www.federalregister.gov/api/v1/documents/2022-27014

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
